Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of “Hold” from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.2333.

A number of research analysts have issued reports on IRWD shares. Citizens Jmp upped their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th.

Insider Activity

In other news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the transaction, the director directly owned 9,188,635 shares in the company, valued at $28,025,336.75. This trade represents a 42.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. Range Financial Group LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $1,436,000. GSA Capital Partners LLP raised its position in shares of Ironwood Pharmaceuticals by 84.7% in the 4th quarter. GSA Capital Partners LLP now owns 571,613 shares of the biotechnology company’s stock valued at $1,926,000 after acquiring an additional 262,084 shares during the period. Hillsdale Investment Management Inc. bought a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $3,897,000. ProShare Advisors LLC boosted its stake in Ironwood Pharmaceuticals by 9.6% during the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 3,170 shares during the last quarter. Finally, Savant Capital LLC grew its holdings in Ironwood Pharmaceuticals by 15.4% during the third quarter. Savant Capital LLC now owns 309,069 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 41,293 shares during the period.

Ironwood Pharmaceuticals Stock Down 2.1%

IRWD stock opened at $3.22 on Wednesday. The company has a market cap of $525.05 million, a P/E ratio of 5.37 and a beta of 0.25. Ironwood Pharmaceuticals has a twelve month low of $0.58 and a twelve month high of $5.78. The business has a fifty day moving average of $3.82 and a 200-day moving average of $3.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.